Leo Edward Gerweck, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Tolerance | 15 | 2024 | 475 | 1.450 |
Why?
|
| Neoplasms, Experimental | 12 | 2014 | 1227 | 1.090 |
Why?
|
| Hydrogen-Ion Concentration | 27 | 2012 | 2477 | 1.070 |
Why?
|
| Hot Temperature | 29 | 2012 | 1442 | 0.870 |
Why?
|
| Cell Survival | 33 | 2024 | 5741 | 0.830 |
Why?
|
| Oxygen | 16 | 2023 | 4251 | 0.660 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2014 | 111 | 0.530 |
Why?
|
| Radiotherapy Dosage | 11 | 2023 | 2911 | 0.520 |
Why?
|
| Chlorambucil | 3 | 2006 | 42 | 0.490 |
Why?
|
| Radiosurgery | 1 | 2024 | 1329 | 0.460 |
Why?
|
| Whole-Body Irradiation | 2 | 2014 | 438 | 0.450 |
Why?
|
| Neutrons | 1 | 2014 | 78 | 0.450 |
Why?
|
| Neoplasms | 16 | 2023 | 22343 | 0.430 |
Why?
|
| Cricetinae | 31 | 2015 | 2416 | 0.420 |
Why?
|
| Fibrosarcoma | 8 | 2003 | 313 | 0.410 |
Why?
|
| Scattering, Radiation | 1 | 2014 | 483 | 0.400 |
Why?
|
| Cell Hypoxia | 7 | 2003 | 659 | 0.370 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2014 | 543 | 0.340 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 604 | 0.340 |
Why?
|
| Radiobiology | 3 | 2023 | 90 | 0.330 |
Why?
|
| Dose-Response Relationship, Radiation | 10 | 2024 | 877 | 0.320 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 1351 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 13 | 2021 | 6105 | 0.300 |
Why?
|
| Cricetulus | 20 | 2015 | 810 | 0.300 |
Why?
|
| Energy Metabolism | 11 | 1995 | 2901 | 0.290 |
Why?
|
| Mice, Nude | 11 | 2017 | 3610 | 0.270 |
Why?
|
| Longevity | 1 | 2014 | 1085 | 0.260 |
Why?
|
| Doxorubicin | 2 | 2006 | 2228 | 0.260 |
Why?
|
| Temperature | 2 | 2012 | 2229 | 0.250 |
Why?
|
| Relative Biological Effectiveness | 4 | 2010 | 313 | 0.240 |
Why?
|
| Hyperthermia, Induced | 6 | 1990 | 414 | 0.240 |
Why?
|
| Neoplasm Transplantation | 9 | 2014 | 2010 | 0.240 |
Why?
|
| Extracellular Space | 5 | 2006 | 562 | 0.230 |
Why?
|
| Adaptation, Physiological | 5 | 1998 | 1312 | 0.230 |
Why?
|
| Ovary | 19 | 1990 | 963 | 0.220 |
Why?
|
| Protons | 4 | 2023 | 1097 | 0.210 |
Why?
|
| Animals | 71 | 2023 | 168887 | 0.190 |
Why?
|
| Mice, Inbred C3H | 10 | 2003 | 915 | 0.180 |
Why?
|
| Mice, SCID | 3 | 2014 | 2626 | 0.180 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2021 | 496 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2001 | 614 | 0.170 |
Why?
|
| Cell Membrane | 6 | 2001 | 3640 | 0.160 |
Why?
|
| Losartan | 1 | 2021 | 263 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 419 | 0.160 |
Why?
|
| CHO Cells | 4 | 1999 | 1376 | 0.160 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2015 | 228 | 0.150 |
Why?
|
| Glucose | 6 | 2006 | 4339 | 0.150 |
Why?
|
| Radiation Dosage | 4 | 2024 | 1952 | 0.150 |
Why?
|
| Antineoplastic Agents | 6 | 2006 | 13639 | 0.150 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 428 | 0.150 |
Why?
|
| Isotretinoin | 1 | 1998 | 135 | 0.140 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1998 | 348 | 0.140 |
Why?
|
| Mice | 32 | 2023 | 81863 | 0.130 |
Why?
|
| Lens, Crystalline | 2 | 2018 | 387 | 0.130 |
Why?
|
| Stromal Cells | 2 | 2014 | 1335 | 0.130 |
Why?
|
| Cell Line | 23 | 2015 | 15563 | 0.130 |
Why?
|
| Lethal Dose 50 | 1 | 2014 | 71 | 0.120 |
Why?
|
| Glioblastoma | 6 | 2017 | 3458 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 1995 | 111 | 0.120 |
Why?
|
| Acclimatization | 3 | 1984 | 113 | 0.120 |
Why?
|
| Intracellular Fluid | 2 | 1999 | 201 | 0.120 |
Why?
|
| Transfection | 4 | 2014 | 5750 | 0.120 |
Why?
|
| Phosphocreatine | 6 | 1995 | 259 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2018 | 424 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 1998 | 910 | 0.110 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 1249 | 0.110 |
Why?
|
| Drug Design | 1 | 1998 | 1042 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 1998 | 3681 | 0.100 |
Why?
|
| Cell Death | 1 | 1998 | 1676 | 0.100 |
Why?
|
| Cells, Cultured | 16 | 2012 | 18979 | 0.100 |
Why?
|
| DNA Repair | 4 | 2010 | 2048 | 0.080 |
Why?
|
| Androgens | 1 | 1997 | 1279 | 0.080 |
Why?
|
| Cysteamine | 3 | 1985 | 24 | 0.080 |
Why?
|
| Adenosine Triphosphate | 6 | 1993 | 2002 | 0.080 |
Why?
|
| DNA Damage | 3 | 2010 | 2464 | 0.080 |
Why?
|
| Apoptosis | 2 | 2015 | 9507 | 0.080 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 1767 | 0.070 |
Why?
|
| Sarcoma, Experimental | 4 | 1995 | 116 | 0.070 |
Why?
|
| Body Fluids | 1 | 1988 | 321 | 0.070 |
Why?
|
| Bone Transplantation | 3 | 1997 | 921 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 13486 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 380 | 0.070 |
Why?
|
| Linear Energy Transfer | 2 | 2010 | 154 | 0.070 |
Why?
|
| Carbon | 1 | 2010 | 673 | 0.070 |
Why?
|
| Muscles | 1 | 1991 | 1576 | 0.070 |
Why?
|
| Indazoles | 1 | 1988 | 306 | 0.060 |
Why?
|
| Humans | 38 | 2024 | 766432 | 0.060 |
Why?
|
| Restriction Mapping | 1 | 2006 | 848 | 0.060 |
Why?
|
| Extremities | 1 | 1990 | 869 | 0.060 |
Why?
|
| Catalase | 2 | 1984 | 215 | 0.060 |
Why?
|
| Oxygen Consumption | 3 | 1988 | 1870 | 0.060 |
Why?
|
| Cell Division | 4 | 1986 | 4474 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 3 | 1997 | 1366 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 17082 | 0.060 |
Why?
|
| Propionibacterium acnes | 1 | 1984 | 59 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2012 | 2764 | 0.060 |
Why?
|
| Kinetics | 5 | 1999 | 6285 | 0.060 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2006 | 235 | 0.060 |
Why?
|
| Cisplatin | 1 | 1990 | 1656 | 0.060 |
Why?
|
| Misonidazole | 1 | 2003 | 33 | 0.060 |
Why?
|
| Glioma | 4 | 2008 | 3498 | 0.060 |
Why?
|
| Phosphorus | 2 | 1998 | 336 | 0.050 |
Why?
|
| Monosaccharides | 1 | 2003 | 64 | 0.050 |
Why?
|
| Cause of Death | 1 | 2014 | 3714 | 0.050 |
Why?
|
| Bone Development | 3 | 1997 | 470 | 0.050 |
Why?
|
| Superoxide Dismutase | 2 | 1984 | 595 | 0.050 |
Why?
|
| Nitroimidazoles | 1 | 2003 | 118 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2003 | 122 | 0.050 |
Why?
|
| Brain Neoplasms | 4 | 2017 | 9101 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 1741 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 1163 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2017 | 3788 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 8925 | 0.050 |
Why?
|
| Cell Physiological Phenomena | 1 | 1982 | 148 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 1006 | 0.040 |
Why?
|
| Phosphates | 3 | 1995 | 763 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 1993 | 421 | 0.040 |
Why?
|
| Time Factors | 16 | 1998 | 40116 | 0.040 |
Why?
|
| X-Rays | 6 | 2000 | 309 | 0.040 |
Why?
|
| Sarcoma | 1 | 1990 | 1802 | 0.040 |
Why?
|
| Radiation Effects | 2 | 1975 | 73 | 0.040 |
Why?
|
| Photons | 1 | 2023 | 588 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2008 | 2141 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 1995 | 4049 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2003 | 2275 | 0.040 |
Why?
|
| Alkalies | 1 | 1998 | 45 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 1998 | 148 | 0.040 |
Why?
|
| Aerobiosis | 2 | 1992 | 100 | 0.040 |
Why?
|
| Acids | 1 | 1998 | 125 | 0.040 |
Why?
|
| Female | 30 | 2021 | 396354 | 0.040 |
Why?
|
| Pyrazoles | 1 | 1988 | 2029 | 0.040 |
Why?
|
| Age Factors | 1 | 2014 | 18395 | 0.040 |
Why?
|
| Pharyngeal Neoplasms | 2 | 1995 | 113 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2001 | 1755 | 0.030 |
Why?
|
| Lung | 3 | 2015 | 10064 | 0.030 |
Why?
|
| Solubility | 1 | 1998 | 1078 | 0.030 |
Why?
|
| Diffusion | 1 | 1998 | 808 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 2629 | 0.030 |
Why?
|
| Heating | 1 | 1996 | 103 | 0.030 |
Why?
|
| Freezing | 1 | 1996 | 310 | 0.030 |
Why?
|
| Combined Modality Therapy | 4 | 1998 | 8536 | 0.030 |
Why?
|
| Partial Pressure | 1 | 1995 | 247 | 0.030 |
Why?
|
| Pentobarbital | 1 | 1995 | 153 | 0.030 |
Why?
|
| Brain | 3 | 2018 | 27156 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1996 | 305 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 547 | 0.030 |
Why?
|
| Neuroglia | 1 | 1980 | 959 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20706 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1997 | 591 | 0.030 |
Why?
|
| Orchiectomy | 1 | 1997 | 465 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1995 | 114 | 0.030 |
Why?
|
| Biological Transport | 1 | 1999 | 2083 | 0.030 |
Why?
|
| Indomethacin | 1 | 1995 | 323 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1995 | 167 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 3605 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 5794 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1996 | 951 | 0.020 |
Why?
|
| Crystallins | 1 | 1972 | 75 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1994 | 711 | 0.020 |
Why?
|
| Head | 1 | 2018 | 926 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6507 | 0.020 |
Why?
|
| Tritium | 1 | 1972 | 707 | 0.020 |
Why?
|
| Proteins | 1 | 1986 | 6002 | 0.020 |
Why?
|
| Weights and Measures | 1 | 1991 | 40 | 0.020 |
Why?
|
| Rats | 5 | 1994 | 23718 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1991 | 410 | 0.020 |
Why?
|
| Fast Neutrons | 1 | 2010 | 18 | 0.020 |
Why?
|
| Nucleotides | 2 | 1990 | 454 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 20129 | 0.020 |
Why?
|
| Cell Cycle | 2 | 1995 | 2925 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 2597 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15390 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 9611 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1990 | 205 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 2473 | 0.020 |
Why?
|
| Male | 11 | 2017 | 363975 | 0.020 |
Why?
|
| Mathematics | 2 | 1983 | 696 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4498 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1991 | 683 | 0.020 |
Why?
|
| Neurilemmoma | 1 | 1994 | 522 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 1995 | 2391 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1990 | 415 | 0.020 |
Why?
|
| Thermodynamics | 1 | 1990 | 578 | 0.020 |
Why?
|
| Immunotherapy | 1 | 1984 | 4749 | 0.020 |
Why?
|
| Mannitol | 1 | 1988 | 176 | 0.020 |
Why?
|
| Organ Specificity | 2 | 2003 | 1966 | 0.020 |
Why?
|
| Ion Channels | 1 | 1993 | 1043 | 0.020 |
Why?
|
| Culture Media | 3 | 1995 | 893 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 175 | 0.020 |
Why?
|
| Lipids | 1 | 1998 | 3319 | 0.020 |
Why?
|
| Adenosine Monophosphate | 1 | 1988 | 232 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1993 | 1591 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12825 | 0.020 |
Why?
|
| Methods | 2 | 1994 | 1065 | 0.020 |
Why?
|
| Skin Window Technique | 2 | 1996 | 22 | 0.020 |
Why?
|
| Glutathione | 2 | 1985 | 589 | 0.020 |
Why?
|
| Culture Techniques | 2 | 1997 | 529 | 0.020 |
Why?
|
| Testosterone | 1 | 1997 | 2495 | 0.020 |
Why?
|
| Probability | 1 | 1990 | 2475 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 2270 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1988 | 10740 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 707 | 0.010 |
Why?
|
| Remission Induction | 1 | 1990 | 2413 | 0.010 |
Why?
|
| Femur | 3 | 1996 | 1318 | 0.010 |
Why?
|
| Regional Blood Flow | 2 | 1997 | 1478 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 1984 | 87 | 0.010 |
Why?
|
| Sulfhydryl Compounds | 1 | 1985 | 296 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1994 | 2559 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1776 | 0.010 |
Why?
|
| Protein Denaturation | 2 | 1988 | 241 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 361 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2002 | 116 | 0.010 |
Why?
|
| Histamine | 1 | 1984 | 496 | 0.010 |
Why?
|
| Anaerobiosis | 1 | 1982 | 140 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 1986 | 792 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 22337 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1993 | 3702 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10438 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 1505 | 0.010 |
Why?
|
| Glycolysis | 1 | 1985 | 838 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1994 | 12061 | 0.010 |
Why?
|
| Radium | 1 | 1981 | 70 | 0.010 |
Why?
|
| Animals, Newborn | 2 | 1996 | 2675 | 0.010 |
Why?
|
| Rabbits | 2 | 1979 | 4752 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 2 | 1994 | 250 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 2430 | 0.010 |
Why?
|
| X-Ray Therapy | 1 | 1977 | 8 | 0.010 |
Why?
|
| Electrons | 1 | 1979 | 264 | 0.010 |
Why?
|
| Rectum | 1 | 2002 | 896 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1997 | 305 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1982 | 3072 | 0.010 |
Why?
|
| Blood Physiological Phenomena | 1 | 1995 | 53 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 4913 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1192 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1995 | 175 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1995 | 220 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 65202 | 0.010 |
Why?
|
| Body Temperature | 1 | 1977 | 781 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1994 | 250 | 0.010 |
Why?
|
| Cartilage | 1 | 1997 | 811 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1995 | 789 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 14466 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 1977 | 723 | 0.010 |
Why?
|
| Histidine | 1 | 1972 | 301 | 0.010 |
Why?
|
| Mitosis | 1 | 1975 | 1176 | 0.010 |
Why?
|
| Models, Biological | 2 | 2000 | 9458 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1990 | 238 | 0.010 |
Why?
|
| Macrophages | 1 | 1984 | 5782 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1994 | 727 | 0.010 |
Why?
|
| Cattle | 1 | 1995 | 3814 | 0.000 |
Why?
|
| Oxidation-Reduction | 2 | 1985 | 2223 | 0.000 |
Why?
|
| Embryo, Mammalian | 1 | 1994 | 1675 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1995 | 1366 | 0.000 |
Why?
|
| Radiometry | 1 | 1972 | 812 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1997 | 2926 | 0.000 |
Why?
|
| Ditiocarb | 1 | 1984 | 6 | 0.000 |
Why?
|
| Cell Movement | 1 | 1977 | 5197 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1984 | 94 | 0.000 |
Why?
|
| Antibodies | 1 | 1993 | 2421 | 0.000 |
Why?
|
| Pentetic Acid | 1 | 1984 | 209 | 0.000 |
Why?
|
| Peroxides | 1 | 1984 | 76 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 3736 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1984 | 276 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 8107 | 0.000 |
Why?
|
| Microcirculation | 1 | 1988 | 1282 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1988 | 1497 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13410 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 1980 | 5860 | 0.000 |
Why?
|
| Peptides | 1 | 1993 | 4344 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1988 | 3946 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 17605 | 0.000 |
Why?
|
| Cysteine | 1 | 1984 | 898 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 11094 | 0.000 |
Why?
|
| Cytological Techniques | 1 | 1981 | 217 | 0.000 |
Why?
|
| Ischemia | 1 | 1986 | 1904 | 0.000 |
Why?
|
| Middle Aged | 1 | 1990 | 223127 | 0.000 |
Why?
|
| Brachytherapy | 1 | 1981 | 1220 | 0.000 |
Why?
|
| Research Design | 1 | 1988 | 6205 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 8042 | 0.000 |
Why?
|
| Mutation | 1 | 1994 | 30220 | 0.000 |
Why?
|